SEC Filing Summary: Coeptis Therapeutics Holdings, Inc. (COEP)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company operating through two segments: Biotechnology (cell therapy platforms for cancer and autoimmune diseases) and Technology (AI-powered marketing and automation). The company is classified as a smaller reporting company and an emerging growth company. As of May 14, 2025, there were 3,513,838 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $62,874 | $0 |
| Net Loss | $(3,420,941) | $(3,001,388) |
| Loss Per Share (Basic & Diluted) | $(1.11) | $(0.08) |
| Cash and Cash Equivalents | $4,268,368 | $1,029,244 |
| Total Assets | $13,453,067 | $8,908,660 |
| Total Liabilities | $5,990,153 | $5,041,434 |
| Convertible Notes Payable (Net) | $1,739,244 | $1,087,873 |
| Notes Payable (In Default) | $100,000 | $100,000 |
| Operating Cash Flow | $(2,366,167) | $(1,902,390) |
| Financing Cash Flow | $6,101,650 | $1,562,500 |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash balances increased significantly from $1.03 million to $4.27 million, driven primarily by a $5.33 million Series A preferred stock offering and $990,000 in proceeds from notes payable.
- Revenue Recognition: The company recorded $62,874 in revenue from technology services (advertising campaigns and webinars), compared to zero in the prior year. A customer deposit of $1.19 million was recorded as a liability.
- Expense Fluctuations: Total operating expenses rose to $4.07 million from $2.92 million. This increase was driven by higher professional services ($2.33M vs $1.18M) and stock-based compensation ($598K vs $97K). Conversely, R&D expenses decreased significantly to $87K from $777K due to the termination of a Shared Services Agreement with Deverra Therapeutics.
- Derivative Gains: The company recognized a $596,120 gain from the change in fair value of derivative liabilities, compared to a $34,875 gain in the prior year, largely due to changes in stock price and volatility assumptions.
- Debt Status: A $100,000 note payable remains in default. However, a $218,750 convertible note to Purple Biotech was paid in full during the quarter.
Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of $101.7 million and recurring net losses. Continued operations depend on raising additional capital.
- Strategic Transactions:
- Merger Agreement: On April 25, 2025, the company entered into a merger agreement to acquire Z Squared, Inc., with a plan to spin out its biotechnology operations to existing shareholders prior to closing.
- SEPA: A Standby Equity Purchase Agreement with Yorkville allows the company to sell up to $20 million of common stock. A related convertible note of $1.3 million was issued.
- Capital Structure: The company completed a $10 million Series A preferred stock offering in February 2025. 6,200 shares of Series A preferred stock were converted to common stock during the quarter.
- Internal Controls: Management concluded that disclosure controls and procedures were effective as of March 31, 2025, following remediation of material weaknesses identified in 2023.
Investor Verification Checklist
- Default Status: Verify the status of the $100,000 note payable listed as "in default" and potential acceleration risks.
- Merger Terms: Review the specific terms of the April 25, 2025 merger with Z Squared, Inc., particularly the "Spin Out" of biotechnology assets and the exchange ratio for shareholders.
- Derivative Valuation: Assess the sensitivity of the $635,489 derivative liability to stock price volatility, as changes significantly impact net income.
- Revenue Sustainability: Evaluate the concentration risk of revenue, which currently relies on two customers accounting for 100% of sales.
- Cash Burn Rate: Monitor the burn rate against the $4.27 million cash balance to determine the runway before further dilution or debt financing is required.